Literature DB >> 3048653

Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.

A W Partin1, J T Isaacs, B Treiger, D S Coffey.   

Abstract

The development of metastatic ability by cancer cells is a multifactorial process whose temporal events are complex and poorly understood. One step in the metastatic process may involve cell motility. Previous studies reported correlations between motility and metastatic ability. Whether this correlation, seen in cancer cells maintained for long periods of time, is an epiphenomenon developing late in the growth of the cancer as a selection artifact of continuous passage, or is critically required for the acquisition of metastatic ability is unknown. To investigate the relationship between cell motility and the acquisition of metastatic ability, advantage was taken of recently developed DNA transfection methods for inducing high metastatic ability in initially low metastatic cancer cells. The Dunning AT2.1 cell line, a clonal rat prostatic cancer cell line with low metastatic ability, was transfected with a plasmid containing the neomycin resistance gene alone or in combination with the v-Harvey-ras oncogene. A series of the transfected cells was isolated by limiting dilution. After the first in vitro passage following transfection, cells were inoculated into rats to characterize their metastatic ability. The same transfectants were simultaneously studied using our visual grading system of cell motility to study the early motility changes associated with newly acquired metastatic ability. The data demonstrate increased membrane ruffling, pseudopodal extension, and cell translation (translocation) in the v-H-ras-transfected cell lines with high metastatic potential.

Entities:  

Mesh:

Year:  1988        PMID: 3048653

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Molecular mechanisms of cell motility.

Authors:  E A Turley
Journal:  Cancer Metastasis Rev       Date:  1992-03       Impact factor: 9.264

2.  Micromotion of mammalian cells measured electrically.

Authors:  I Giaever; C R Keese
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  Keratinocyte growth factor-induced motility of breast cancer cells.

Authors:  X P Zang; J T Pento
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Polarized ion transport during migration of transformed Madin-Darby canine kidney cells.

Authors:  A Schwab; K Gabriel; F Finsterwalder; G Folprecht; R Greger; A Kramer; H Oberleithner
Journal:  Pflugers Arch       Date:  1995-09       Impact factor: 3.657

Review 5.  Molecular and cellular markers for metastatic prostate cancer.

Authors:  C W Rinker-Schaeffer; W B Isaacs; J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

Review 6.  Cellular motility and prostatic carcinoma metastases.

Authors:  J L Mohler
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

7.  An anti-invasive concentration of the alkyl-lysophospholipid ET-18-OCH3 enhances the motility of embryonal chick heart cells cultured on solid substrate.

Authors:  N A van Larebeke; E A Bruyneel; M M Mareel
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

8.  LKB1 suppresses p21-activated kinase-1 (PAK1) by phosphorylation of Thr109 in the p21-binding domain.

Authors:  Atsuko Deguchi; Hiroyuki Miyoshi; Yasushi Kojima; Katsuya Okawa; Masahiro Aoki; Makoto M Taketo
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

Review 9.  Hyaluronan and cell locomotion.

Authors:  E A Turley
Journal:  Cancer Metastasis Rev       Date:  1992-03       Impact factor: 9.264

10.  E-cadherin suppression directs cytoskeletal rearrangement and intraepithelial tumor cell migration in 3D human skin equivalents.

Authors:  Addy Alt-Holland; Yulia Shamis; Kathleen N Riley; Teresa M DesRochers; Norbert E Fusenig; Ira M Herman; Jonathan A Garlick
Journal:  J Invest Dermatol       Date:  2008-06-05       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.